Takeda Secures Global Rights from Ovid Therapeutics
Takeda Secures Global Rights from Ovid Therapeutics to Develop and Commercialize Soticlestat for the Treatment of Children and Adults with Dravet Syndrome and Lennox-Gastaut Syndrome.
Ovid eligible to receive up to 856M in payments, including a 196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales
− Original 2017 collaboration between Ovid and Takeda to conclude; Ovid will have no further development or milestone obligations.
In addition, Ovid will receive tiered royalties beginning in the low double-digits and up to 20 percent on sales of soticlestat, if approved and commercialized.
Takeda intends to initiate Phase 3 studies of soticlestat in children and young adults with DS and LGS in calendar year Q2 2021.
finance.yahoo.com/news/takeda-secures-global-rights-ovid-120000107.html
Ovid eligible to receive up to 856M in payments, including a 196M upfront payment, regulatory and commercial milestone payments and tiered double-digit royalties on product sales
− Original 2017 collaboration between Ovid and Takeda to conclude; Ovid will have no further development or milestone obligations.
In addition, Ovid will receive tiered royalties beginning in the low double-digits and up to 20 percent on sales of soticlestat, if approved and commercialized.
Takeda intends to initiate Phase 3 studies of soticlestat in children and young adults with DS and LGS in calendar year Q2 2021.
finance.yahoo.com/news/takeda-secures-global-rights-ovid-120000107.html
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.